The National Institute of Diabetes and Digestive and Kidney Diseases estimates that 1 in 7 people affected by a kidney disease have anemia. In addition, more than 37 million United States adults may have chronic kidney disease. The rising prevalence of kidney diseases due to unhealthy dietary habits, sedentary lifestyle and increased alcohol indulgence complement the risk of renal anemia. Therefore, several companies are engaged in research and development to develop high-efficacy drugs to manage the condition, indicating a robust drug pipeline.
Major companies involved in the renal anemia pipeline drugs market include Hoffmann-La Roche, Astellas Pharma Inc., and Bayer.
Leading drugs currently under pipeline include AND017, FG-2216, Roxadustat, and PEG-EPO injections among others.
Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for renal anemia as they are offering breakthrough designations to manage the condition.
The Renal anemia Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing renal anemia clinical trials. It covers various aspects related to the details of renal anemia drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The renal anemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from renal anemia.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing renal anemia pipeline development activities are covered. Moreover, renal anemia collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Renal anemia (also known as anemia of kidney disease) is a side effect of chronic kidney disease, leading to reduced production of erythropoietin (EPO). Erythropoietin is a vital hormone released by the kidneys and it helps in the production of red blood cells. Renal anemia gets worse with the progression of chronic kidney disease. Common symptoms include pale skin, dizziness, fatigue, shortness of breath or cold intolerance.
Renal anemia treatment alternatives include iron supplements and vitamins. However, medicines are advised to treat severe symptoms of the disease. In February 2023, GSK received the United States FDA approval for Jesduvroq (daprodustat), intended to treat chronic kidney disease associated anemia in adults on dialysis. Patients on hemodialysis may also receive a subcutaneous erythropoiesis-stimulating agent (ESA) for the treatment of anemia.
This section of the report covers the analysis of renal anemia drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s renal anemia therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for renal anemia. There are around 206 drugs in phase III of renal anemia drugs.
The drug molecules categories covered under renal anemia pipeline analysis include erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), iron supplements and vitamin supplements. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a relatively newer class of medications that stabilise hypoxia inducing factors and promote the production of erythropoietin naturally.
The EMR report for the renal anemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in renal anemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for renal anemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of renal anemia drug candidates.
As a part of a multi-center, open-label non-randomized, active-controlled Phase 2 study, this oral drug is under investigation to treat renal anemia. It is sponsored by Kind Pharmaceuticals LLC and is administered to patients with chronic kidney disease on dialysis.
Currently, in Phase 2 of an interventional study, FG-2216 is under evaluation for its efficacy and safety to treat patients with renal anemia who are not on dialysis or receiving erythropoietin. The study is sponsored by FibroGen and enrols 145 participants.
Researchers at the Peking University First Hospital are conducting a Phase 4 multi-center, randomized, controlled study to assess the effect of roxadustate in patients on peritoneal dialysis. It is orally hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with proven efficacy and safety in prior Phase 3 clinical trials.
It is an experimental drug developed by Angde Biotech Pharmaceutical Co., Ltd. and is being explored for optimal dosage and administration to treat patients with renal anemia. PEG-EPO Injection is in Phase 2 of a multi-center, randomized, open-label, positive controlled clinical study that has an enrollment of 150 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Renal Anemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for renal anemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into renal anemia collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Global Acute Kidney Injury Treatment Market
Polycystic Kidney Disease Drugs Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share